Skip to ContentSkip to Navigation
University of Groningenfounded in 1614  -  top 100 university
Close
About us Latest news Press information

Haisma, Prof. Hidde

Hidde Haisma
Hidde Haisma

Hidde J. Haisma (1957) is professor of Pharmaceutic Gene Modulation at the Pharmacy department of the Faculty of Science and Engineering. He studied medical biology at Utrecht University and has worked in the US (including at Harvard Medical School) and at VU University Amsterdam. In 2000 he was appointed Professor of Pharmaceutic Gene Modulation at the University of Groningen.

Haisma conducts research into the development of drugs that can influence human genes in order to cure diseases. Haisma is editor of a number of journals in the field of gene therapy and has written over 100 publications and various patent applications in his field of study. Haisma is a board member of the Nederlandse Vereniging voor Gen- en Celtherapie (Dutch Society for Gene and Cell Therapy) and of the European Society of Gene and Cell Therapy. He is also a member of the Gene Doping Expert Group of the World Anti-Doping Agency (WADA). October 2016 he received a 100,000 US dollar grant from the WADA for his research project that will focus on the development of a gene doping detection assay based on next generation sequencing.

Video

Previously in the news

Article NOS
Article NOS

Contact and further information

See profile page

Publications

2020

Liu, B., Diaz Arguello, O. A., Chen, D., Chen, S., Saber, A., & Haisma, H. J. (2020). CRISPR-mediated ablation of overexpressed EGFR in combination with sunitinib significantly suppresses renal cell carcinoma proliferation. PLoS ONE, 15(5), [0232985]. https://doi.org/10.1371/journal.pone.0232985
van den Boom, N. A. C., Winters, M., Haisma, H. J., & Moen, M. H. (2020). Efficacy of Stem Cell Therapy for Tendon Disorders: A Systematic Review. Orthopaedic journal of sports medicine, 8(4). https://doi.org/10.1177/2325967120915857
Liu, B., Chen, D., Chen, S., Saber, A., & Haisma, H. (2020). Transcriptional activation of cyclin D1 via HER2/HER3 contributes to EGFR-TKI resistance in lung cancer. Biochemical Pharmacology, 178, [114095]. https://doi.org/10.1016/j.bcp.2020.114095

2019

Saber, A., Liu, B., Ebrahimi, P., & Haisma, H. J. (2020). CRISPR/Cas9 for overcoming drug resistance in solid tumors. Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences, 28(1), 295-304. https://doi.org/10.1007/s40199-019-00240-z
Liu, B., Chen, S., Chen, D., Cao, F., Zwinderman, M., Kiemel, D., Aïssi, M., Dekker, F. J., Haisma, H. J., & La Rose, A. (2020). Inhibition of histone deacetylase 1 (HDAC1) and HDAC2 enhances CRISPR/Cas9 genome editing. Nucleic Acids Research, 48(2), 517-532. https://doi.org/10.1093/nar/gkz1136
de Boer, E. N., van der Wouden, P. E., Johansson, L. F., van Diemen, C. C., & Haisma, H. J. (2019). A next-generation sequencing method for gene doping detection that distinguishes low levels of plasmid DNA against a background of genomic DNA. Gene Therapy, 26(7-8), 338-346. https://doi.org/10.1038/s41434-019-0091-6
Liu, B., Saber, A., & Haisma, H. J. (2019). CRISPR/Cas9: A powerful tool for identification of new targets for cancer treatment. Drug Discovery Today, 24(4), 955-970. https://doi.org/10.1016/j.drudis.2019.02.011
Liu, B., Song, S., Setroikromo, R., Chen, S., Hu, W., Chen, D., van der Wekken, A. J., Melgert, B. N., Timens, W., van den Berg, A., Saber, A., & Haisma, H. J. (2019). CX Chemokine Receptor 7 Contributes to Survival of KRAS-Mutant Non-Small Cell Lung Cancer upon Loss of Epidermal Growth Factor Receptor. Cancers, 11(4), [455]. https://doi.org/10.3390/cancers11040455
Zhang, B., Liu, B., Chen, D., Setroikromo, R., Haisma, H. J., & Quax, W. J. (2019). Histone Deacetylase Inhibitors Sensitize TRAIL-Induced Apoptosis in Colon Cancer Cells. Cancers, 11(5), [645]. https://doi.org/10.3390/cancers11050645

2017

Bosch, van den, T., Leus, N. G. J., Wapenaar, H., Boichenko, A., Hermans, J., Bischoff, R., Haisma, H. J., & Dekker, F. J. (2017). A 6-alkylsalicylate histone acetyltransferase inhibitor inhibits histone acetylation and pro-inflammatory gene expression in murine precision-cut lung slices. Pulmonary Pharmacology & Therapeutics, 44, 88-95. https://doi.org/10.1016/j.pupt.2017.03.006
Leus, N. G. J., van den Bosch, T., van der Wouden, P. E., Krist, K., Ourailidou, M. E., Eleftheriadis, N., Kistemaker, L. E. M., Bos, S., Gjaltema, R. A. F., Mekonnen, S. A., Bischoff, R., Gosens, R., Haisma, H. J., & Dekker, F. J. (2017). HDAC1-3 inhibitor MS-275 enhances IL10 expression in RAW264.7 macrophages and reduces cigarette smoke-induced airway inflammation in mice. Scientific Reports, 7, [45047]. https://doi.org/10.1038/srep45047
Pas, H. I. M. F. L., Moen, M. H., Haisma, H. J., & Winters, M. (2017). No evidence for the use of stem cell therapy for tendon disorders: a systematic review. British Journal of Sports Medicine, 51(13), 996-1004. https://doi.org/10.1136/bjsports-2016-096794
Pas, H. I. M. F. L., Winters, M., Haisma, H. J., Koenis, M. J. J., Tol, J. L., & Moen, M. H. (2017). Stem cell injections in knee osteoarthritis: a systematic review. British Journal of Sports Medicine, 51(15), 1125-1133. https://doi.org/10.1136/bjsports-2016-096793
Wapenaar, H., van den Bosch, T., Leus, N. G. J., van der Wouden, P. E., Eleftheriadis, N., Hermans, J., Hailu, G. S., Rotili, D., Mai, A., Domling, A., Bischoff, R., Haisma, H. J., & Dekker, F. J. (2017). The relevance of K-i calculation for bi-substrate enzymes illustrated by kinetic evaluation of a novel lysine (K) acetyltransferase 8 inhibitor. European Journal of Medicinal Chemistry, 136, 480-486. https://doi.org/10.1016/j.ejmech.2017.05.015

2016

Arabpour, M., Cool, R., Faber, K. N., Quax, W. J., & Haisma, H. J. (2017). Receptor-specific TRAIL as a means to achieve targeted elimination of activated hepatic stellate cells. Journal of Drug Targeting, 25(4), 360-369. https://doi.org/10.1080/1061186X.2016.1262867
Haisma, H., & Schalekamp, T. (2016). Apothekersopleidingen klaar voor de toekomst: Domeinspecifiek referentiekader en Raamplan Farmacie geven onderwijs richting. Pharmaceutisch Weekblad, 151(24), 18-19. http://www.pw.nl/achtergrond/2016/apothekersopleidingen-klaar-voor-de-toekomst
Haisma, H., & Schalekamp, T. (2016, May 10). Domeinspecifiek referentiekader & Raam plan Farmacie 2016. https://www.knmp.nl/downloads/domeinspecifiek-referentiekader-en-raamplan-farmacie-2016.pdf/view
Leus, N. G. J., van der Wouden, P. E., van den Bosch, T., Hooghiemstra, W. T. R., Ourailidou, M. E., Kistemaker, L. E. M., Bischoff, R., Gosens, R., Haisma, H. J., & Dekker, F. J. (2016). HDAC 3-selective inhibitor RGFP966 demonstrates anti-inflammatory properties in RAW 264.7 macrophages and mouse precision-cut lung slices by attenuating NF-κB p65 transcriptional activity. Biochemical Pharmacology, 58-74. https://doi.org/10.1016/j.bcp.2016.03.010
Haisma, H. (2016). Nederlands farmaceutisch onderwijs wereldwijd voorop. Pharmaceutisch Weekblad, 151(50), 21.
van den Bosch, T., Boichenko, A., Leus, N. G. J., Ourailidou, M. E., Wapenaar, H., Rotili, D., Mai, A., Imhof, A., Bischoff, R., Haisma, H. J., & Dekker, F. J. (2016). The histone acetyltransferase p300 inhibitor C646 reduces pro-inflammatory gene expression and inhibits histone deacetylases. Biochemical Pharmacology, 102, 130-140. https://doi.org/10.1016/j.bcp.2015.12.010

2014

Haisma, H. (2014). Assessment of preclinical gene therapy studies worldwide. (3 ed.) COGEM.
Haisma, H. (2014). Sport: vliegensvlugge genen. In Genen en Gezondheid (Vol. Cahier 1). Stichting Biowetenschappen en Maatschappij.
Arabpour, M., Poelstra, K., Helfrich, W., Bremer, E., & Haisma, H. J. (2014). Targeted elimination of activated hepatic stellate cells by an anti-epidermal growth factor-receptor single chain fragment variable antibody-tumor necrosis factor-related apoptosis-inducing ligand (scFv425-sTRAIL). Journal of gene medicine, 16(9-10), 281-290. https://doi.org/10.1002/jgm.2776
Arabpour, M., Poelstra, K., Helfrich, W., Bremer, E., & Haisma, H. J. (2014). Targeted Elimination of Activated Hepatic Stellate Cells by Anti-EGF-Receptor scFv-sTRAIL Fusion Protein. Molecular Therapy, 22(suppl. 1), S121-S121.

2013

Wisastra, R., Kok, P. A. M., Eleftheriadis, N., Baumgartner, M. P., Camacho, C. J., Haisma, H. J., & Dekker, F. J. (2013). Discovery of a novel activator of 5-lipoxygenase from an anacardic acid derived compound collection. Bioorganic & Medicinal Chemistry, 21(24), 7763-7778. https://doi.org/10.1016/j.bmc.2013.10.015
van der Gronde, T., de Hon, O., Haisma, H. J., & Pieters, T. (2013). Gene doping: An overview and current implications for athletes. British Journal of Sports Medicine, 47(11), 670-678. https://doi.org/10.1136/bjsports-2012-091288
van Dijk, R., Miranda, P. S. M., Riviere, C., ten Bloemendaal, L., van Gorp, J., Duijst, S., de Waart, D. R., Beuers, U., Haisma, H. J., & Bosma, P. J. (2013). Polyinosinic acid blocks adeno-associated virus macrophage endocytosis in vitro and enhances adeno-associated virus liver directed gene therapy in vivo. Human Gene Therapy, 24(12), A135.
van Dijk, R., Montenegro-Miranda, P. S., Riviere, C., Schilderink, R., ten Bloemendaal, L., van Gorp, J., Duijst, S., de Waart, D. R., Beuers, U., Haisma, H. J., & Bosma, P. J. (2013). Polyinosinic Acid Blocks Adeno-Associated Virus Macrophage Endocytosis In Vitro and Enhances Adeno-Associated Virus Liver-Directed Gene Therapy In Vivo. Human Gene Therapy, 24(9), 807-813. https://doi.org/10.1089/hum.2013.086
Kuldo, J. M., Asgeirsdottir, S. A., Zwiers, P. J., Bellu, A. R., Rots, M. G., Schalk, J. A. C., Ogawara, K. I., Trautwein, C., Banas, B., Haisma, H. J., Molema, G., & Kamps, J. A. A. M. (2013). Targeted adenovirus mediated inhibition of NF-kappa B-dependent inflammatory gene expression in endothelial cells in vitro and in vivo. Journal of Controlled Release, 166(1), 57-65. https://doi.org/10.1016/j.jconrel.2012.12.016

2012

Wisastra, R., Ghizzoni, M., Boltjes, A., Haisma, H. J., & Dekker, F. J. (2012). Anacardic acid derived salicylates are inhibitors or activators of lipoxygenases. Bioorganic & Medicinal Chemistry, 20(16), 5027-5032. https://doi.org/10.1016/j.bmc.2012.06.019
Farinha Antunes, I., Doorduin, J., Haisma, H. J., Elsinga, P. H., van Waarde, A., Willemsen, A. T. M., Dierckx, R. A., & de Vries, E. F. J. (2012). F-18-FEAnGA for PET of beta-Glucuronidase Activity in Neuroinflammation. Journal of Nuclear Medicine, 53(3), 451-458. https://doi.org/10.2967/jnumed.111.096388
Antunes, I. F., Haisma, H. J., Elsinga, P. H., Sijbesma, J. W. A., van Waarde, A., Willemsen, A. T. M., Dierckx, R. A., & de Vries, E. F. J. (2012). In vivo evaluation of [F-18]FEAnGA-Me: a PET tracer for imaging beta-glucuronidase (beta-GUS) activity in a tumor/inflammation rodent model. Nuclear Medicine and Biology, 39(6), 854-863. https://doi.org/10.1016/j.nucmedbio.2012.02.002
Farinha Antunes, I., Haisma, H. J., Elsinga, P. H., van Waarde, A., Willemsen, A. T. M., Dierckx, R. A., & de Vries, E. F. J. (2012). In Vivo Evaluation of 1-O-(4-(2-Fluoroethyl-Carbamoyloxymethyl)-2-Nitrophenyl)-O-beta-D-Glucopyronuronate: A Positron Emission Tomographic Tracer for Imaging beta-Glucuronidase Activity in a Tumor/Inflammation Rodent Model. Molecular imaging, 11(1), 77-87. https://doi.org/10.2310/7290.2011.00029
Farinha Antunes, I., Haisma, H. J., Elsinga, P. H., Di Gialleonardo, V., van Waarde, A., Willemsen, A. T. M., Dierckx, R. A., & de Vries, E. F. J. (2012). Induction of beta-Glucuronidase Release by Cytostatic Agents in Small Tumors. Molecular pharmaceutics, 9(11), 3277-3285. https://doi.org/10.1021/mp300327w
Haisma, H. J. (2012). Physical Enhancement. In J. Savulescu, R. ter Meulen, & G. Kahane (Eds.), Enhancing human capacities (pp. 257-265). Wiley-Blackwell.
Ghizzoni, M., Wu, J., Gao, T., Haisma, H. J., Dekker, F. J., & Zheng, Y. G. (2012). 6-alkylsalicylates are selective Tip60 inhibitors and target the acetyl-CoA binding site. European Journal of Medicinal Chemistry, 47(1), 337-344. https://doi.org/10.1016/j.ejmech.2011.11.001

2011

Wisastra, R., Poelstra, K., Bischoff, R., Maarsingh, H., Haisma, H. J., & Dekker, F. J. (2011). Antibody-Free Detection of Protein Tyrosine Nitration in Tissue Sections. ChemBioChem, 12(13), 2016-2020. https://doi.org/10.1002/cbic.201100148
Varkouhi, A. K., Scholte, M., Storm, G., & Haisma, H. J. (2011). Endosomal escape pathways for delivery of biologicals. Journal of Controlled Release, 151(3), 220-228. https://doi.org/10.1016/j.jconrel.2010.11.004
Ghizzoni, M., Haisma, H. J., Maarsingh, H., & Dekker, F. J. (2011). Histone acetyltransferases are crucial regulators in NF-kappa B mediated inflammation. Drug Discovery Today, 16(11-12), 504-511. https://doi.org/10.1016/j.drudis.2011.03.009
Wisastra, R., Ghizzoni, M., Maarsingh, H., Minnaard, A. J., Haisma, H. J., & Dekker, F. J. (2011). Isothiazolones; thiol-reactive inhibitors of cysteine protease cathepsin B and histone acetyltransferase PCAF. Organic and Biomolecular Chemistry, 9(6), 1817-1822. https://doi.org/10.1039/c0ob00464b
Haisma, H. J., & Bellu, A. R. (2011). Pharmacological Interventions for Improving Adenovirus Usage in Gene Therapy. Molecular pharmaceutics, 8(1), 50-55. https://doi.org/10.1021/mp100310h

2010

van Zeeburg, H. J. T., van Beusechem, V. W., Huizenga, A., Haisma, H. J., Korokhov, N., Gibbs, S., Leemans, C. R., & Brakenhoff, R. H. (2010). Adenovirus retargeting to surface expressed antigens on oral mucosa. Journal of gene medicine, 12(4), 365-376. https://doi.org/10.1002/jgm.1447
Ghizzoni, M., Boltjes, A., de Graaf, C., Haisma, H. J., & Dekker, F. J. (2010). Improved inhibition of the histone acetyltransferase PCAF by an anacardic acid derivative. Bioorganic & Medicinal Chemistry, 18(16), 5826-5834. https://doi.org/10.1016/j.bmc.2010.06.089
Haisma, H. J., Kamps, G. K., Bouma, A., Geel, T. M., Rots, M. G., Kariath, A., & Bellu, A. R. (2010). Selective targeting of adenovirus to alpha(v)beta(3) integrins, VEGFR2 and Tie2 endothelial receptors by angio-adenobodies. International Journal of Pharmaceutics, 391(1-2), 155-161. https://doi.org/10.1016/j.ijpharm.2010.02.032
Farinha Antunes, I., Haisma, H. J., Elsinga, P. H., Dierckx, R. A., & de Vries, E. F. J. (2010). Synthesis and Evaluation of [F-18]-FEAnGA as a PET Tracer for beta-Glucuronidase Activity. BIOCONJUGATE CHEMISTRY, 21(5), 911-920. https://doi.org/10.1021/bc9004602

2009

ABEN RENE WILHELMUS, MARIE., SCHEEREN JOHAN, WILHELM., CORNELISSEN JEROEN JOHANNES LAMBERTUS, MARIA., DE VOS, DICK., & Haisma, H. (2009). IPC No. C07H 15/ 26 A I. ESTER OF GLUCURONIDE PRODRUG OF ANTHRACYCLINE AND METHOD OF PREPARATION AND USE IN TUMOR-SELECTIVE CHEMOTHERAPY. (Patent No. JP2009215295).
Aben, R. W. M., de Vos, D., Haisma, H. J., Cornelissen, J. J. L. M., & Scheeren, J. W. (2009, Mar 1). Esters of glucuronide prodrugs of anthracyclines and method of preparation and use in tumor-selective chemotherapy. Google Patents.
Dekker, F. J., & Haisma, H. J. (2009). Histone acetyl transferases as emerging drug targets. Drug Discovery Today, 14(19-20), 942-948. https://doi.org/10.1016/j.drudis.2009.06.008
Dekker, F. J., Ghizzoni, M., van der Meer, N., Wisastra, R., & Haisma, H. J. (2009). Inhibition of the PCAF histone acetyl transferase and cell proliferation by isothiazolones. Bioorganic & Medicinal Chemistry, 17(2), 460-466. https://doi.org/10.1016/j.bmc.2008.12.008
Ghizzoni, M., Haisma, H. J., & Dekker, F. J. (2009). Reactivity of isothiazolones and isothiazolone-1-oxides in the inhibition of the PCAF histone acetyltransferase. European Journal of Medicinal Chemistry, 44(12), 4855-4861. https://doi.org/10.1016/j.ejmech.2009.07.025
Haisma, H. J., Boesjes, M., Beerens, A. M., van der Strate, B. W. A., Curiel, D. T., Plueddemann, A., Gordon, S., & Bellu, A. R. (2009). Scavenger Receptor A: A New Route for Adenovirus 5. Molecular pharmaceutics, 6(2), 366-374. https://doi.org/10.1021/mp8000974

2008

Riezebos-Brilman, A., Walczak, M., Regts, J., Rots, M. G., Kamps, G., Dontje, B., Haisma, H. Y., Wilschut, J., & Daemen, T. (2008). A comparative study on the immunotherapeutic efficacy of recombinant Semliki Forest virus and adenovirus vector systems in a murine model for cervical cancer (vol 14, pg 1695, 2007). Gene Therapy, 15(1), 66. https://doi.org/10.1038/sj.gt.3303084
Johnson, T. S., Mahnke, K., Storn, V., Schoenfeld, K., Ring, S., Nettelbeck, D. M., Haisma, H. J., Le Gall, F., Kontermann, R. E., & Enk, A. H. (2008). Inhibition of Melanoma Growth by Targeting of Antigen to Dendritic Cells via an Anti-DEC-205 Single-Chain Fragment Variable Molecule. Clinical Cancer Research, 14(24), 8169-8177. https://doi.org/10.1158/1078-0432.CCR-08-1474
Schoemaker, M. H., Rots, M. G., Beljaars, L., Ypma, A. Y., Jansen, P. L. M., Poelstra, K., Moshage, A., & Haisma, H. J. (2008). PDGF-receptor beta-targeted adenovirus redirects gene transfer from hepatocytes to activated stellate cells. Molecular pharmaceutics, 5(3), 399-406. https://doi.org/10.1021/mp700118p
Haisma, H. J., Kamps, J. A. A. M., Plantinga, J. A., Rots, M. G., Bellu, A. R., & Kamps, G. (2008). Polyinosinic acid enhances delivery of adenovirus vectors in vivo by preventing sequestration in liver macrophages. Journal of general virology, 89, 1097-1105. https://doi.org/10.1099/vir.0.83495-0
Bremer, E., van Dam, G. M., de Bruyn, M., van Riezen, M., Dijkstra, M., Kamps, G., Helfrich, W., & Haisma, H. (2008). Potent Systemic Anticancer Activity of Adenovirally Expressed EGFR-Selective TRAIL Fusion Protein. Molecular Therapy, 16(12), 1919-1926. https://doi.org/10.1038/mt.2008.203
Beerens, A. M. J., Rots, M. G., Bermudez, B., De Vries, E. F. J., & Haisma, H. J. (2008). Secretion of thymidine kinase to increase the effectivity of suicide gene therapy results in the loss of enzymatic activity. Journal of Drug Targeting, 16(1), 26-35.
Farinha Antunes, I., Haisma, H. J., & de Vries, E. F. J. (2008). Tumor-specific activation of prodrugs: Is there a role for nuclear medicine? Nuclear Medicine Communications, 29(10), 845-846. https://doi.org/10.1097/MNM.0b013e3283094efc

2007

Riezebos-Brilman, A., Walczak, M., Regts, J., Rots, M., Kamps, G., Dontje, B., Haisma, H., Wilschut, J., & Daemen, T. (2007). A comparative study on the immunotherapeutic efficacy of recombinant Semliki Forest virus and adenovirus vector systems in a murine model for cervical cancer. Gene Therapy, 14(24), 1695-1704. https://doi.org/10.1038/sj.gt.3303036
Carette, J. E., Graat, H. C. A., Schagen, F. H. E., Mastenbroek, D. C. J., Rots, M. G., Haisma, H. J., Groothuis, G. M. M., Schaap, G. R., Bras, J., Kaspers, G. J. L., Wuisman, P. I. J. M., Gerritsen, W. R., & van Beusechem, V. W. (2007). A conditionally replicating adenovirus with strict selectivity in killing cells expressing epidermal growth factor receptor. Virology, 361(1), 56-67. https://doi.org/10.1016/j.virol.2006.11.011
Gommans, W. M., McLaughlin, P. M. J., Lindhout, B. I., Segal, D. J., Wiegman, D. J., Haisma, H. J., van der Zaal, B. J., & Rots, M. G. (2007). Engineering zinc finger protein transcription factors to downregulate the epithelial glycoprotein-2 promoter as a novel anti-cancer treatment. Molecular carcinogenesis, 46(5), 391-401. https://doi.org/10.1002/mc.20289
Beerens, A. M. J., Rots, M. G., de Vries, E. F. J., & Haisma, H. J. (2007). Fusion of herpes simplex virus thymidine kinase to VP22 does not result in intercellular trafficking of the protein. International journal of molecular medicine, 19(5), 841-849.
Gommans, W. M., McLaughlin, P. M. J., Schalk, J. A. C., Groothuis, G. M. M., Haisma, H. J., & Rots, M. G. (2007). Highly efficient and carcinoma-specific adenoviral replication restricted by the EGP-2 promoter. Journal of Controlled Release, 117(1), 1-10. https://doi.org/10.1016/j.jconrel.2006.10.006

2006

Rots, MG., Elferink, MGL., Gommans, WM., Oosterhuis, D., Schalk, JAC., Curiel, DT., Olinga, P., Haisma, HJ., & Groothuis, GMM. (2006). An ex vivo human model system to evaluate specificity of replicating and non-replicating gene therapy agents. Journal of gene medicine, 8(1), 35-41. https://doi.org/10.1002/jgm.815
Stoff-Khalili, M. A., Rivera, A. A., Le, L. P., Stoff, A., Everts, M., Contreras, J. L., Chen, D., Teng, L., Rots, M. G., Haisma, H. J., Rocconi, R. P., Bauerschmitz, G. J., Rein, D. T., Yamamoto, M., Siegal, G. P., Dall, P., Michael Mathis, J., & Curiel, D. T. (2006). Employment of liver tissue slice analysis to assay hepatotoxicity linked to replicative and nonreplicative adenoviral agents. Cancer Gene Therapy, 13(6), 606-618. https://doi.org/10.1038/sj.cgt.7700934
Ogawara, K., Kuldo, JM., Oosterhuis, K., Kroesen, BJ., Rots, MG., Trautwein, C., Kimura, T., Haisma, HJ., & Molema, G. (2006). Functional inhibition of NF-kappa B signal transduction in alpha v alpha beta 3 integrin expressing endothelial cells by using RGD-PEG-modified adenovirus with a mutant I kappa B gene. Arthritis Research and Therapy, 8(1), [32]. https://doi.org/10.1186/ar1885
Haisma, HJ., & de Hon, O. (2006). Gene doping. International Journal of Sports Medicine, 27(4), 257-266. https://doi.org/10.1055/s-2006-923986
Haisma, HJ., De Hon, O., Sollie, P., & Vorstenbosch, J. (2006). Genetische doping. Nederlands Tijdschrift voor Klinische Chemie en Laboratoriumgeneeskunde, 31(1), 19.
Karpanen, T., Wirzenius, M., Mäkinen, T., Veikkola, T., Haisma, H. J., Achen, M. G., Stacker, S. A., Pytowski, B., Ylä-Herttuala, S., & Alitalo, K. (2006). Lymphangiogenic growth factor responsiveness is modulated by postnatal lymphatic vessel maturation. American Journal of Pathology, 169(2), 708-718. https://doi.org/10.2353/ajpath.2006.051200
Mahasreshti, PJ., Kataram, M., Wu, HJ., Yalavarthy, LP., Carey, D., Dent, P., Chada, S., Alvarez, RD., Haisma, HJ., Fisher, PB., & Curiel, DT. (2006). Ovarian cancer targeted adenoviral-mediated mda-7/IL-24 gene therapy. Gynecologic Oncology, 100(3), 521-532. https://doi.org/10.1016/j.ygyno.2005.08.042
Visser, A. E., Verschure, P. J., Gommans, W. M., Haisma, H. J., & Rots, M. G. (2006). Step into the Groove: Engineered Transcription Factors as Modulators of Gene Expression. In JC. Hall, JC. Dunlap, T. Friedmann, & VanHeyningen (Eds.), ADVANCES IN GENETICS (pp. 131-+). (Advances in Genetics; Vol. 56). Academic Press. https://doi.org/10.1016/S0065-2660(06)56004-3
Gommans, WM., van Eert, SJ., McLaughlin, PMJ., Harmsen, MC., Yamamoto, M., Curiel, DT., Haisma, HJ., & Rots, MG. (2006). The carcinoma-specific epithelial glycoprotein-2 promoter controls efficient and selective gene expression in an adenoviral context. Cancer Gene Therapy, 13(2), 150-158. https://doi.org/10.1038/sj.cgt.7700882
Gommans, W. M., Oosterhuis, D., Dmitriev, I., Schaack, J., Curiel, D. T., Haisma, H. J., & Rots, M. G. (2006). Towards a double controlled conditionally replicative adenovirus for potent and specific melanoma cell kill. Journal of Controlled Release, 116(2), E64-E66. https://doi.org/10.1016/j.jconrel.2006.09.052

2005

Oosterhoff, D., Overmeer, RM., de Graaf, M., van der Meulen, IH., Giaccone, G., van Beusechem, VW., Haisma, HJ., Pinedo, HM., & Gerritsen, WR. (2005). Adenoviral vector-mediated expression of a gene encoding secreted, EpCAM-targeted carboxylesterase-2 sensitises colon cancer spheroids to CPT-11. British Jounal of Cancer, 92(5), 882-887. https://doi.org/10.1038/sj.bjc.6602362
Roy, H., Bhardwaj, S., Babu, M., Jauhiainen, S., Herzig, KH., Bellu, AR., Haisma, HJ., Carmeliet, P., Alitalo, K., & Yla-Herttuala, S. (2005). Adenovirus-mediated gene transfer of placental growth factor to perivascular tissue induces angiogenesis via upregulation of the expression of endogenous vascular endothelial growth factor-A. Human Gene Therapy, 16(12), 1422-1428.
Gommans, WM., Haisma, HJ., & Rots, MG. (2005). Engineering zinc finger protein transcription factors: The therapeutic relevance of switching endogenous gene expression on or off at command. Journal of Molecular Biology, 354(3), 507-519. https://doi.org/10.1016/j.jmb.2005.06.082
Lu, B., Makhija, SK., Nettelbeck, DM., Rivera, AA., Komarova, S., Zhou, F., Yamamoto, M., Haisma, HJ., Alvarez, RD., Curiel, DT., & Zhu, ZB. (2005). Evaluation of tumor-specific promoter activities in melanoma. Gene Therapy, 12(4), 330-338. https://doi.org/10.1038/sj.gt.3302385
Kraaij, R., van Rijswijk, ALCT., Haisma, HJ., & Bangma, CH. (2005). Prostate specific membrane antigen (PSMA) is a tissue-specific target for adenoviral transduction of prostate cancer in vitro. Prostate, 62(3), 253-259. https://doi.org/10.1002/pros.20150
Buursma, A. R., Beerens, A., de Vries, E. F. J., van Waarde, A., Rots, M., Hospers, G. A. P., Vaalburg, W., & Haisma, H. J. (2005). The human norepinephrine transporter in combination with C-11-m-hydroxyephedrine as a reporter gene/reporter probe for PET of gene therapy. Journal of Nuclear Medicine, 46(12), 2068-2075.
Haisma, H. J., & de Hon, O. (2005). Ziek, beter, best: van gentherapie tot genetische doping. In Beter dan Goed, over Genetica en de toekomst van Topsport (pp. 120 - 137). Veen Magazines B.V..

2004

Nevalainen, T. J., Scheeren, H. W., Pinedo, H. M., Haisma, H. J., & Boven, E. (2004). A methylester of the glucuronide prodrug DOX-GA3 for improvement of tumor-selective chemotherapy. Biochemical Pharmacology, 68(11), 2273-2281. https://doi.org/10.1016/j.bcp.2004.08.004
Kirby, TO., Rivera, A., Rein, D., Ulasov, N. V., Breidenbach, M., Kataram, M., Contreras, JL., Krumdieck, C., Yamamoto, M., Rots, MG., Haisma, HJ., Alvarez, RD., Mahasreshti, PJ., & Curiel, DT. (2004). A novel ex vivo model system for evaluation of conditionally replicative adenoviruses therapeutic efficacy and toxicity. Clin.Cancer Res., 10(24), 8697 - 8703.
Ogawara, K., Rots, M., Kok, R. J., Moorlag, H. E., van Loenen - Weemaes, A., Meijer, D. K. F., Haisma, H. J., & Molema, I. (2004). A novel strategy to modify adenovirus tropism and enhance transgene delivery to activated vascular endothelial cells in vitro and in vivo. Human Gene Therapy, 15(5), 433 - 443. https://doi.org/10.1089/10430340460745766
Rots, M., Gommans, W. M., Dmitriev, I., Oosterhuis, D., Seki, T., Curiel, D. T., & Haisma, H. J. (2004). A platform for constucting infectivity-enhanced fiber-mosaic adenoviruses genetically modified to express two fiber types. Gene Therapy and Molecular Biology, 8, 1 - 8.
Leath, CA., Kataram, M., Bhagavatula, P., Gopalkrishnan, RV., Dent, P., Fisher, PB., Pereboev, A., Carey, D., Lebedeva, N. V., Haisma, HJ., Alvarez, RD., Curiel, DT., & Mahasreshti, PJ. (2004). Infectivity enhanced adenoviral-mediated mda-7/IL-24 gene therapy for ovarian carcinoma. Gynecologic Oncology, 94(2), 352 - 362. https://doi.org/10.1016/j.ygyno.2004.04.028
Pinedo, H. M., Oosterhoff, D., Van der Meulen-Muileman, I. H., Gerritsen, W. R., Haisma, H. J., & Boven, E. (2004). Pronounced antitumor efficacy by extracellular activation of a doxorubicin-glucuronide prodrug after adenoviral vector-mediated expression of a human antibody-enzyme fusion protein. Human Gene Therapy, 15(3), 229 - 238.
Schoemaker, M., Conde de la Rosa, L., Buist-Homan, M., Vrenken, T. E., Havinga, R., Poelstra, K., Haisma, H. J., Jansen, P. LM., & Moshage, A. J. H. (2004). Tauroursodeoxycholic acid protects rat hepatocytes from bile acid-induced apoptosis via activation of survival pathways. Hepatology, 39(6), 1563 - 1573. https://doi.org/10.1002/hep.20246

2003

Brandao, JG., Scheper, RJ., Lougheed, SM., Curiel, DT., Tillman, BW., Gerritsen, WR., van den Eertwegh, AJM., Pinedo, HM., Haisma, HJ., & de Gruijl, TD. (2003). CD40-targeted adenoviral gene transfer to dendritic cells through the use of a novel bispecific single-chain Fv antibody enhances cytotoxic T cell activation. Vaccine, 21(19-20), 2268-2272. https://doi.org/10.1016/S0264-410X(03)00050-1
van Beusechem, V. W., Mastenbroek, D. C., Van den Doel, P. B., Lamfers, M. L., Grill, J., Wurdinger, T., Haisma, H. J., Pinedo, H. M., & Gerritsen, W. R. (2003). Conditionally replicative adenovirus expressing a targeting adapter molecule exhibits enhanced oncolytic potency on CAR-deficient tumors. Gene Therapy, 10(23), 1982-1991. https://doi.org/10.1038/sj.gt.3302103
Pinedo, H. M., Quadir, R., Haisma, H. J., & Boven, E. (2003). Cytosolic beta-glycosidases for activation of glycoside prodrugs of daunorubicin. Biochem.Pharmacol., 65(11), 1875-1881. https://doi.org/10.1016/S0006-2952(03)00183-7
Oosterhoff, D., Witlox, M. A., van Beusechem, V. W., Haisma, H. J., Schaap, G. R., Bras, J., Kruyt, W., Molenaar, B., Boven, E., Wuisman, P. I., Pinedo, H. M., & Gerritsen, W. R. (2003). Gene-directed enzyme prodrug therapy for osteosarcoma: Sensitization to CPT-11 in vitro and in vivo by adenoviral delivery of a gene encoding secreted carboxylesterase-2. Mol.Cancer Ther., 2(8), 765-771.
Mahasreshti, P. J., Kataram, M., Wang, M. H., Stockard, C. R., Grizzle, W. E., Carey, D., Siegal, G. P., Haisma, H. J., Alvarez, R. D., & Curiel, D. T. (2003). Intravenous delivery of adenovirus-mediated soluble FLT-1 results in liver toxicity. Clin.Cancer Res., 9(7), 2701 - 2710.
Fonseca, M. J., Jagtenberg, J. C., Haisma, H. J., & Storm, G. (2003). Liposome-mediated targeting of enzymes to cancer cells for site-specific activation of prodrugs: Comparison with the corresponding antibody-enzyme conjugate. Pharmaceutical Research, 20(3), 423-428.
Beerens, A. M., Al Hadithy, A. F., Rots, M., & Haisma, H. J. (2003). Protein transduction domains and their utility in gene therapy. Curr.Gene Ther., 3(5), 486 - 494.
Schoemaker, M., Gommans, W. M., Conde de la Rosa, L., Buist-Homan, M., Klok, P., Trautwein, C., van Goor, H., Poelstra, K., Haisma, H. J., Jansen, P. LM., & Moshage, A. J. H. (2003). Resistance of rat hepatocytes against bile acid-induced apoptosis in cholestatic liver injury is due to nuclear factor-kappa B activation. Journal of Hepatology, 39(2), 153-161. https://doi.org/10.1016/S0168-8278(03)00214-9
Haisma, HJ., & Rots, MG. (2003). State of the art in gene therapy. In CTS. Sibinga, & LFM. DeLeij (Eds.), CELLULAR ENGINEERING AND CELLULAR THERAPIES (pp. 171-187). (DEVELOPMENTS IN HEMATOLOGY AND IMMUNOLOGY; Vol. 38). Springer.
Rots, MG., Curiel, DT., Gerritsen, WR., & Haisma, HJ. (2003). Targeted cancer gene therapy: the flexibility of adenoviral gene therapy vectors. J.Control Release, 87(1-3), 159-165. https://doi.org/10.1016/S0168-3659(02)00360-7
Bruell, D., Stocker, M., Huhn, M., Redding, N., Kupper, M., Schumacher, P., Paetz, A., Bruns, CJ., Haisma, HJ., Fischer, R., Finnern, R., & Barth, S. (2003). The recombinant anti-EGF receptor immunotoxin 425(scFv)-ETA' suppresses growth of a highly metastatic pancreatic carcinoma cell line. Int.J.Oncol., 23(4), 1179-1186.
Uil, T. G., Haisma, H. J., & Rots, M. (2003). Therapeutic modulation of endogenous gene function by agents with designed DNA-sequence specificities. Nucleic Acids Res., 31(21), 6064-6078. https://doi.org/10.1093/nar/gkg815

2002

Boven, E., Oosterhoff, D., van der Meulen-Muileman, IH., Huls, GA., Gerritsen, WR., Haisma, HJ., & Pinedo, HM. (2002). A fully human anti-Ep-CAM scFv-beta-glucuronidase fusion protein for selective chemotherapy with a glucuronide prodrug. British Jounal of Cancer, 86(5), 811-818. https://doi.org/10.1038/sj/bjc/6600143
Boven, E., Scheeren, H. W., Haisma, HJ., & Pinedo, HM. (2002). Beta-glucuronidase-mediated drug release. Current Pharmaceutical Design, 8(15), 1391-1403. https://doi.org/10.2174/1381612023394485
Arafat, WO., Gomez-Navarro, J., Buchsbaum, DJ., Xiang, J., Casado, E., Barker, SD., Mahasreshti, PJ., Haisma, HJ., Barnes, MN., Siegal, GP., Alvarez, RD., Hemminki, A., Nettelbeck, DM., & Curiel, DT. (2002). Effective single chain antibody (scFv) concentrations in vivo via adenoviral vector mediated expression of secretory scFv. Gene Therapy, 9(4), 256-262. https://doi.org/10.1038/sj.gt.3301639
van Beusechem, VW., Grill, J., Mastenbroek, DCJ., Wickham, TJ., Roelvink, PW., Haisma, HJ., Lamfers, MLM., Dirven, CMF., Pinedo, HM., & Gerritsen, WR. (2002). Efficient and selective gene transfer into primary human brain tumors by using single-chain antibody-targeted adenoviral vectors with native tropism abolished. Journal of Virology, 76(6), 2753-2762. https://doi.org/10.1128/JVI.76.6.2753-2762.2002
Witlox, M. A., van Beusechem, V. W., Grill, J., Haisma, H. J., Schaap, G., Bras, J., Van Diest, P., De Gast, A., Curiel, D. T., Pinedo, H. M., Gerritsen, W. R., & Wuisman, P. I. (2002). Epidermal growth factor receptor targeting enhances adenoviral vector based suicide gene therapy of osteosarcoma. J Gene Med, 4(5), 510 - 516. https://doi.org/10.1002/jgm.308
van der Poel, HG., Molenaar, B., van Beusechem, VW., Haisma, HJ., Rodriguez, R., Curiel, DT., & Gerritsen, WR. (2002). Epidermal growth factor receptor targeting of replication competent adenovirus enhances cytotoxicity in bladder cancer. Journal of Urology, 168(1), 266-272.
Dirven, CMF., Grill, J., Lamfers, MLM., Van der Valk, P., Leonhart, AM., Van Beusechem, VW., Haisma, HJ., Pinedo, HM., Curiel, DT., Vandertop, WP., & Gerritsen, WR. (2002). Gene therapy for meningioma: improved gene delivery with targeted adenoviruses. Journal of Neurosurgery, 97(2), 441-449.
Haisma, H. J. (2002). Genegen genen, van genese tot genezen. s.n.
de Gruijl, TD., Luykx-de Bakker, SA., Tillman, BW., van den Eertwegh, AJM., Buter, J., Lougheed, SM., van der Bij, GJ., Safer, AM., Haisma, HJ., Curiel, DT., Scheper, RJ., Pinedo, HM., & Gerritsen, WR. (2002). Prolonged maturation and enhanced transduction of dendritic cells migrated from human skin explants after in situ delivery of CD40-targeted adenoviral vectors. Journal of Immunology, 169(9), 5322-5331.
Roks, AJM., Henning, RH., Buikema, H., Pinto, YM., Kraak, MJJ., Tio, RA., de Zeeuw, D., Haisma, HJ., Wilschut, J., & van Gilst, WH. (2002). Recombinant Semliki Forest virus as a vector system for fast and selective in vivo gene delivery into balloon-injured rat aorta. Gene Therapy, 9(2), 95-101. https://doi.org/10.1038/sj/gt/3301632
Oosterhoff, D., Pinedo, HM., van der Meulen, IH., Sone, T., Kruyt, FA., van Beusechem, VW., Haisma, HJ., & Gerritsen, WR. (2002). Secreted and tumour targeted human carboxylesterase for activation of irinotecan. British Jounal of Cancer, 87(6), 659-664. https://doi.org/10.1038/sj.bjc.6600519
Haisma, H. J., & Rots, M. G. (2002). Targeting of adenoviral gene therapy vectors: the flexibility of chemical and molecular conjugation. Vector Targeting for Therapeutic Gene Delivery, 123-141.
de Graaf, M., van der Meulen-Muileman, I. H., Pinedo, H. M., & Haisma, H. J. (2002). 34 Expression of scFvs and scFv Fusion Proteins in Eukaryotic Cells. In Antibody Phage Display (pp. 379-387). Springer.

2001

Houba, PHJ., Boven, E., van der Meulen-Muileman, IH., Leenders, R. G. G., Scheeren, JW., Pinedo, HM., & Haisma, H. J. (2001). A novel doxorubicin-glucuronide prodrug DOX-GA3 for tumour-selective chemotherapy: distribution and efficacy in experimental human ovarian cancer. British Jounal of Cancer, 84(4), 550-557. https://doi.org/10.1054/bjoc.2000.1640
De Graaf, M., Van Veen, IC., Van Der Meulen-Muileman, IH., Gerritsen, WR., Pinedo, HM., & Haisma, HJ. (2001). Cloning and characterization of human liver cytosolic beta-glycosidase. Biochemical Journal, 356, 907-910.
Grill, J., Van Beusechem, VW., Van de Valk, P., Dirven, CMF., Leonhart, A., Pherai, DS., Haisma, HJ., Pinedo, HM., Curiel, DT., & Gerritsen, WR. (2001). Combined targeting of adenoviruses to integrins and epidermal growth factor receptors increases gene transfer into primary glioma cells and spheroids. Clinical Cancer Research, 7(3), 641-650.
van Beusechem, VW., Grill, J., Mastenbroek, DCJ., Haisma, HJ., Wickham, TJ., Roelvink, PW., Pinedo, HM., & Gerritsen, WR. (2001). Highly specific adenovirus vectors for targeted cancer gene therapy. Cancer Gene Therapy, 8(9), 688-689.
Houba, PHJ., Boven, E., van der Meulen-Muileman, IH., Leenders, R. G. G., Scheeren, J. W., Pinedo, HM., & Haisma, H. J. (2001). Pronounced antitumor efficacy of doxorubicin when given as the prodrug DOX-GA3 in combination with a monoclonal antibody beta-glucuronidase conjugate. International Journal of Cancer, 91(4), 550-554.
Heideman, DAM., Snijders, PJF., Craanen, ME., Bloemena, E., Meijer, CJLM., Meuwissen, SGM., van Beusechem, VW., Pinedo, HM., Curiel, DT., Haisma, HJ., & Gerritsen, WR. (2001). Selective gene delivery toward gastric and esophageal adenocarcinoma cells via EpCAM-targeted adenoviral vectors. Cancer Gene Therapy, 8(5), 342-351.
de Gruijl, TD., van den Eertwegh, AJM., Haisma, HJ., Curiel, DT., Gerritsen, WR., Pinedo, HM., & Scheper, RJ. (2001). Targeted adenoviral transduction and activation of cutaneous dendritic cells: studies in a human skin explant model. Cancer Gene Therapy, 8(9), 685-685.
Heideman, DAM., Snijders, PJF., Craanen, ME., Bloemena, E., Meijer, CJLM., Meuwissen, SGM., Beusechem, VW., Pinedo, HM., Curiel, DT., Haisma, HJ., & Gerritsen, WR. (2001). Targeting of adenoviral vectors towards gastric and esophageal adenocarcinoma cells. Gastroenterology, 120(5), A614.

2000

Helfrich, W., Haisma, HJ., Magdolen, N. V., Luther, T., Bom, VJJ., Westra, J., van der Hoeven, R., Kroesen, BJ., Molema, G., & de Leij, L. (2000). A rapid and versatile method for harnessing scFv antibody fragments with various biological effector functions. Journal of Immunological Methods, 237(1-2), 131-145.
Heideman, DA., Snijders, PJ., Craanen, ME., Bloemena, E., van Beusechem, VW., Pinedo, HM., Meijer, CJ., Meuwissen, SG., Curiel, DT., Haisma, HJ., & Gerritsen, WR. (2000). EpCAM is a marker for (pre-) malignant lesions of the stomach, and a good target for specific gene transfer towards gastric carcinoma cells. Gastroenterology, 118(4), A704-A704.
van Beusechem, VW., van Rijswijk, ALCT., van Es, HHG., Haisma, HJ., Pinedo, HM., & Gerritsen, WR. (2000). Recombinant adenovirus vectors with knobless fibers for targeted gene transfer. Gene Therapy, 7(22), 1940-1946.
Haisma, HJ., van Beusechem, VW., Curiel, DT., Pinedo, HM., & Gerritsen, WR. (2000). Targeted enzymes for molecular chemotherapy. Cancer Gene Therapy, 7(8), 1208-1208.
Haisma, HJ., Grill, J., Curiel, DT., Hoogeland, S., van Beusechem, VW., Pinedo, HM., & Gerritsen, WR. (2000). Targeting of adenoviral vectors through a bispecific single-chain antibody. Cancer Gene Therapy, 7(6), 901-904.

1999

Fonseca, MJ., Storm, G., Hennink, WE., Gerritsen, WR., & Haisma, HJ. (1999). Cationic polymeric gene delivery of beta-glucuronidase for doxorubicin prodrug therapy. Journal of gene medicine, 1(6), 407-414.
Fonseca, MJ., Haisma, HJ., Klaasen, S., Vingerhoeds, MH., & Storm, G. (1999). Design of immuno-enzymosomes with maximum enzyme targeting capability: effect of the enzyme density on the enzyme targeting capability and cell binding properties. Biochimica et Biophysica Acta-Biomembranes, 1419(2), 272-282.
Houba, PHJ., Boven, E., van der Meulen-Muileman, IH., Leenders, RGG., Scheeren, JW., Pinedo, HM., & Haisma, HJ. (1999). Distribution and pharmacokinetics of the prodrug daunorubicin-GA3 in nude mice bearing human ovarian cancer xenografts. Biochemical Pharmacology, 57(6), 673-680.
Leenders, RGG., Damen, EWP., Bijsterveld, EJA., Scheeren, HW., Houba, PHJ., van der Meulen-Muileman, IH., Boven, E., & Haisma, HJ. (1999). Novel anthracycline-spacer-beta-glucuronide, -beta-glucoside, and -beta-galactoside prodrugs for application in selective chemotherapy. Bioorganic & Medicinal Chemistry, 7(8), 1597-1610.
Bangma, CH., Kraaij, R., van Rijswijk, A., Haisma, HJ., van Beusechem, V. W., & Gerritsen, W. (1999). Transductional targeting of adenoviral vectors to prostate cancer in vitro. Prostate Cancer and Prostatic Diseases, 2, S5-S5.
Haisma, HJ., Pinedo, HM., van Rijswijk, A., van der Muelen-Muileman, N. V., Sosnowski, BA., Ying, W., van Beusechem, VW., Tillman, BW., Gerritsen, WR., & Curiel, DT. (1999). Tumor-specific gene transfer via an adenoviral vector targeted to the pan-carcinoma antigen EpCAM. Gene Therapy, 6(8), 1469-1474.

1998

Damen, E. WP., de Vos, D., Haisma, H. J., Houba, P. HJ., Leenders, R. GG., & Scheeren, J. W. (1998, Jan 1). Anthracycline prodrugs, method for preparation as well as their use in selective chemotherapy. Google Patents.
Haisma, HJ., Brakenhoff, RH., Van der Meulen-Muileman, I. H., Pinedo, HM., & Boven, E. (1998). Construction and characterization of a fusion protein of single-chain anti-carcinoma antibody 323/A3 and human beta-glucuronidase. Cancer Immunology Immunotherapy, 45(5), 266-272. https://doi.org/10.1007/s002620050442
Haisma, HJ., Sernee, MF., Hooijberg, E., Brakenhoff, RH., van den Meulen-Mulleman, IH., Pinedo, HM., & Boven, E. (1998). Construction and characterization of a fusion protein of single-chain anti-CD20 antibody and human beta-glucuronidase for antibody-directed enzyme prodrug therapy. Blood, 92(1), 184-190.
de Bont, H. BA., Leenders, R. GG., Scheeren, J. W., Haisma, H. J., & de Vos, D. (1998). IPC No. C07H 13/ 12 A I. Paclitaxel prodrugs, method for preparation as well as their use in selective chemotherapy. (Patent No. US5760072).
Houba, PHJ., Boven, E., Erkelens, CAM., Leenders, RGG., Scheeren, JW., Pinedo, HM., & Haisma, HJ. (1998). The efficacy of the anthracycline prodrug daunorubicin-GA3 in human ovarian cancer xenografts. British Jounal of Cancer, 78(12), 1600-1606. https://doi.org/10.1038/bjc.1998.729
Houba, PHJ., Boven, E., Leenders, RGG., van der Meulen-Mulleman, IH., Scheeren, JW., Pinedo, HM., & Haisma, HJ. (1998). Tumor selective activation of a doxorubicin prodrug (DOX-GA3) in human ovarian cancer xenografts. Annals of Oncology, 9, 51-51.

1997

Haisma, HJ., Pinedo, HM., vandeMeulenMuileman, IH., Houba, PHJ., Leenders, RGG., Scheeren, JW., & Boven, E. (1997). Daunorubicin-GA3, a novel prodrug for use in gene therapy. Cancer Gene Therapy, 4(5), 307-307.
Storm, G., Vingerhoeds, MH., Crommelin, DJA., & Haisma, HJ. (1997). Immunoliposomes bearing enzymes (immuno-enzymosomes) for site-specific activation of anticancer prodrugs. Advanced Drug Delivery Reviews, 24(2-3), 225-231.
deBont, DBA., Leenders, RGG., Haisma, HJ., vanderMeulenMuileman, N. V., & Scheeren, HW. (1997). Synthesis and biological activity of beta-glucuronyl carbamate-based prodrugs of paclitaxel as potential candidates for ADEPT. Bioorganic & Medicinal Chemistry, 5(2), 405-414.
Meijs, WE., Haisma, HJ., Klok, RP., vanGog, FB., Kievit, E., Pinedo, HM., & Herscheid, JDM. (1997). Zirconium-labeled monoclonal antibodies and their distribution in tumor-bearing nude mice. Journal of Nuclear Medicine, 38(1), 112-118.

1996

Meijs, WE., Haisma, HJ., VanderSchors, R., Wijbrandts, R., VandenOever, K., Klok, RP., Pinedo, HM., & Herscheid, JDM. (1996). A facile method for the labeling of proteins with zirconium isotopes. Nuclear Medicine and Biology, 23(4), 439-448.
Houba, PHJ., Leenders, RGG., Boven, E., Scheeren, JW., Pinedo, HM., & Haisma, HJ. (1996). Characterization of novel anthracycline prodrugs activated by human beta-glucuronidase for use in antibody-directed enzyme prodrug therapy. Biochemical Pharmacology, 52(3), 455-463.
Kievit, E., Pinedo, HM., Schluper, HMM., Haisma, HJ., & Boven, E. (1996). Comparison of the monoclonal antibodies 17-1A and 323/A3: The influence of the affinity on tumour uptake and efficacy of radioimmunotherapy in human ovarian cancer xenografts. British Jounal of Cancer, 73(4), 457-464.
Vingerhoeds, MH., Haisma, HJ., Belliot, SO., Smit, RHP., Crommelin, DJA., & Storm, G. (1996). Immunoliposomes as enzyme-carriers (immuno-enzymosomes) for antibody-directed enzyme prodrug therapy (ADEPT): Optimization of prodrug activating capacity. Pharmaceutical Research, 13(4), 604-610.
Houba, PHJ., Boven, E., & Haisma, HJ. (1996). Improved characteristics of a human beta-glucuronidase-antibody conjugate after deglycosylation for use in antibody-directed enzyme prodrug therapy. BIOCONJUGATE CHEMISTRY, 7(5), 606-611.

1995

Haisma, H., VANMUIJEN, M., SCHEFFER, G., SCHEPER, RJ., PINEDO, HM., & BOVEN, E. (1995). A MONOCLONAL-ANTIBODY AGAINST HUMAN BETA-GLUCURONIDASE FOR APPLICATION IN ANTIBODY-DIRECTED ENZYME PRODRUG THERAPY. Hybridoma, 14(4), 377-382.
LEENDERS, RGG., GERRITS, KAA., RUIJTENBEEK, R., SCHEEREN, HW., Haisma, H., & BOVEN, E. (1995). BETA-GLUCURONYL CARBAMATE BASED PRO-MOIETIES DESIGNED FOR PRODRUGS IN ADEPT. Tetrahedron Letters, 36(10), 1701-1704.
Haisma, H. (1995). MAB-105 ANTI-HUMAN BETA-GLUCURONIDASE. Hybridoma, 14(4), 402-402. https://doi.org/10.1089/hyb.1995.14.402
BUIST, MR., KENEMANS, P., VANKAMP, GJ., & Haisma, H. (1995). Minor human antibody response to a mouse and chimeric monoclonal antibody after a single i.v. infusion in ovarian carcinoma patients: a comparison of five assays. Cancer Immunology Immunotherapy, 40(1), 24-30. https://doi.org/10.1007/BF01517232
Boven, E., Haisma, H. J., & Pinedo, H. M. (1995). Monoclonale antilichamen in diagnose en therapie van patienten met kanker. Nederlands Tijdschrift voor Geneeskunde, 139(49), 2552-2558. https://www.ntvg.nl/artikelen/monoklonale-antilichamen-voor-diagnostiek-en-therapie-bij-de-oncologische-pati%C3%ABnt/volledig
Leenders, RGG., Scheeren, HW., Houba, PHJ., Boven, E., & Haisma, HJ. (1995). Synthesis and evaluation of novel daunomycin-phosphate -sulfate -beta-glucuronide and -beta-glucoside prodrugs for application in ADEPT. Bioorganic & Medicinal Chemistry Letters, 5(24), 2975-2980.

1994

PLAIZIER, MABD., ROOS, JC., TEULE, GJJ., VANDIEREN, EB., DENHOLLANDER, W., Haisma, H., DEJAGER, RL., & VANLINGEN, A. (1994). COMPARISON OF NONINVASIVE APPROACHES TO RED MARROW DOSIMETRY FOR RADIOLABELED MONOCLONAL-ANTIBODIES. European Journal of Nuclear Medicine, 21(3), 216-222.
MEIJS, WE., HERSCHEID, JDM., Haisma, H., WIJBRANDTS, R., VANLANGEVELDE, F., VANLEUFFEN, PJ., MOOY, R., & PINEDO, HM. (1994). PRODUCTION OF HIGHLY PURE NO-CARRIER ADDED ZR-89 FOR THE LABELING OF ANTIBODIES WITH A POSITRON EMITTER. Applied Radiation and Isotopes, 45(12), 1143-1147.

1993

VINGERHOEDS, MH., Haisma, H., VANMUIJEN, M., VANDERIJT, RBJ., CROMMELIN, DJA., & STORM, G. (1993). A NEW APPLICATION FOR LIPOSOMES IN CANCER-THERAPY - IMMUNOLIPOSOMES BEARING ENZYMES (IMMUNO-ENZYMOSOMES) FOR SITE-SPECIFIC ACTIVATION OF PRODRUGS. FEBS Letters, 336(3), 485-490.

1992

Haisma, H., BOVEN, E., VANMUIJEN, M., DEJONG, J., VANDERVIJGH, WJF., & PINEDO, HM. (1992). A MONOCLONAL ANTIBODY-BETA-GLUCURONIDASE CONJUGATE AS ACTIVATOR OF THE PRODRUG EPIRUBICIN-GLUCURONIDE FOR SPECIFIC TREATMENT OF CANCER. British Jounal of Cancer, 66(3), 474-478.
Haisma, H. J., Boven, E., van Muijen, M., de Vries, R., & Pinedo, H. M. (1992). Analysis of a conjugate between anti-carcinoembryonic antigen monoclonal antibody and alkaline phosphatase for specific activation of the prodrug etoposide phosphate. Cancer Immunology Immunotherapy, 34(5), 343-348. https://doi.org/10.1007/BF01741556
Haisma, H., PINEDO, HM., SILVA, CA., & BOVEN, E. (1992). DETERMINATION OF THE IMMUNOREACTIVE FRACTION OF RADIOLABELED MONOCLONAL-ANTIBODIES DIRECTED AGAINST INTRACELLULAR ANTIGENS. Journal of Immunological Methods, 154(1), 55-60.
MEIJS, WE., HERSCHEID, JDM., Haisma, H., & PINEDO, HM. (1992). EVALUATION OF DESFERAL AS A BIFUNCTIONAL CHELATING AGENT FOR LABELING ANTIBODIES WITH ZR-89. Applied Radiation and Isotopes, 43(12), 1443-1447.

1991

Haisma, H., PINEDO, HM., KESSEL, MAP., VANMUIJEN, M., ROOS, JC., PLAIZIER, MABD., MARTENS, HJM., DEJAGER, R., & BOVEN, E. (1991). HUMAN-IGM MONOCLONAL ANTIBODY-16.88 - PHARMACOKINETICS AND IMMUNOGENICITY IN COLORECTAL-CANCER PATIENTS. Jnci-Journal of the national cancer institute, 83(24), 1813-1819.
MAAS, IWHM., BOVEN, E., PINEDO, HM., SCHLUPER, HMM., & Haisma, H. (1991). THE EFFECTS OF GAMMA-INTERFERON COMBINED WITH 5-FLUOROURACIL OR 5-FLUORO-2'-DEOXYURIDINE ON PROLIFERATION AND ANTIGEN EXPRESSION IN A PANEL OF HUMAN COLORECTAL-CANCER CELL-LINES. International Journal of Cancer, 48(5), 749-756.
BOVEN, E., Haisma, H., BRIL, H., MARTENS, HJM., VANLINGEN, A., DENHOLLANDER, W., KESSEL, MAP., DEJAGER, RL., & ROOS, JC. (1991). TUMOR-LOCALIZATION WITH I-131-LABELED HUMAN-IGM MONOCLONAL-ANTIBODY 16.88 IN ADVANCED COLORECTAL-CANCER PATIENTS. European Journal of Cancer, 27(11), 1430-1436.

1990

Haisma, H., KESSEL, MAP., SILVA, C., VANMUIJEN, M., ROOS, JC., BRIL, H., MARTENS, HJM., MCCABE, R., & BOVEN, E. (1990). HUMAN-IGM MONOCLONAL-ANTIBODY 16.88 - PHARMACOKINETICS AND DISTRIBUTION IN MOUSE AND MAN. British Jounal of Cancer, 62, 40-43.

1989

MOSELEY, KR., KNAPP, RC., BOVEN, E., PINEDO, HM., & Haisma, H. (1989). Increased CA125 elevation in patients after administration of i-131-OC125 caused by human anti-mouse antibodies. British Jounal of Cancer, 59(2), 316-317.
QUAK, JJ., BALM, AJM., BRAKKEE, JGP., SCHEPER, RJ., Haisma, H., BRAAKHUIS, BJM., MEIJER, CJLM., & SNOW, GB. (1989). LOCALIZATION AND IMAGING OF RADIOLABELED MONOCLONAL-ANTIBODY AGAINST SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK IN TUMOR-BEARING NUDE-MICE. International Journal of Cancer, 44(3), 534-538.

1988

MOSELEY, KR., KNAPP, RC., & Haisma, H. (1988). AN ASSAY FOR THE DETECTION OF HUMAN ANTI-MURINE IMMUNOGLOBULINS IN THE PRESENCE OF CA125-ANTIGEN. Journal of Immunological Methods, 106(1), 1-6.
Haisma, H., MOSELEY, KR., BATTAILE, AI., GRIFFITHS, TC., ZURAWSKI, VR., & KNAPP, RC. (1988). BIODISTRIBUTION, PHARMACOKINETICS AND IMAGING OF I-131-LABELLED OC125 IN OVARIAN-CANCER. International Journal of Cancer, 109-113.
Haisma, H., MOSELEY, KR., BATTAILE, A., GRIFFITHS, TC., & KNAPP, RC. (1988). DISTRIBUTION AND PHARMACOKINETICS OF RADIOLABELED MONOCLONAL-ANTIBODY OC-125 AFTER INTRAVENOUS AND INTRAPERITONEAL ADMINISTRATION IN GYNECOLOGIC TUMORS. American Journal of Obstetrics and Gynecology, 159(4), 843-848.
MOSELEY, KR., BATTAILE, A., KNAPP, RC., & Haisma, H. (1988). LOCALIZATION OF RADIOLABELED F(AB')2 FRAGMENTS OF MONOCLONAL-ANTIBODIES IN NUDE-MICE BEARING INTRAPERITONEALLY GROWING HUMAN OVARIAN-CANCER XENOGRAFTS. International Journal of Cancer, 42(3), 368-372.
Verheijen, R. H. M., Massuger, L. F. A. G., Kenemans, P., Haisma, H. J., & Epenetos, A. A. (1988). Polymorphic epithelial mucin and CA125-bearing glycoprotein as targets for imaging and therapy with monoclonal antibodies. CANCER TREATMENT REVIEWS, 11-12, 145-172.
Haisma, H. (1988). IPC No. G01N 33/ 60 A I. Single vial technique for radiolabeling protein. (Patent No. US4775638).

1987

Haisma, H., BATTAILE, A., STRADTMAN, EW., KNAPP, RC., & ZURAWSKI, VR. (1987). ANTIBODY-ANTIGEN COMPLEX-FORMATION FOLLOWING INJECTION OF OC125 MONOCLONAL-ANTIBODY IN PATIENTS WITH OVARIAN-CANCER. International Journal of Cancer, 40(6), 758-762.
Haisma, H., MOSELEY, KR., BATTAILE, A., ZURAWSKI, VR., & KNAPP, RC. (1987). BIODISTRIBUTION, PHARMACOKINETICS AND IMAGING OF I-131-LABELED OC125 IN PATIENTS WITH OVARIAN-CARCINOMA. British Jounal of Cancer, 56(4), 519-519.
Haisma, H. J. (1987). Monoclonal antibodies and cancer: studies on the use of monoclonal antibodies for imaging and therapy of cancer, with special emphasis on ovarian carcinoma. s.n.
BOERMAN, OC., THOMAS, CMG., SEGERS, MFG., KENEMANS, P., LOVGREN, T., ZURAWSKI, VR., Haisma, H., & POELS, LG. (1987). TIME-RESOLVED IMMUNOFLUOROMETRIC ASSAY FOR THE OVARIAN CARCINOMA-ASSOCIATED ANTIGENIC DETERMINANT CA-125 IN SERUM. Clinical Chemistry, 33(12), 2191-2194.

1986

Haisma, H., LIGTENBERG, M., DULLENS, HFJ., & DENOTTER, W. (1986). HIGHER ADCC OF MURINE PERITONEAL-CELLS AFTER IMMUNIZATION WITH ALLOGENIC TUMOR-CELLS AS COMPARED WITH STIMULATION BY ADRIAMYCIN, BCG, AND THIOGLYCOLATE. Cellular immunology, 101(2), 454-462.
Haisma, H., BATTAILE, A., KNAPP, RC., & ZURAWSKI, VR. (1986). IMMUNE-COMPLEXES OF OC125-CA125 FOLLOWING INTRAVENOUS-INJECTION OF THE RADIOLABELED MONOCLONAL-ANTIBODY INTO OVARIAN-CANCER PATIENTS. British Jounal of Cancer, 54(3), 533-534.
Haisma, H., HILGERS, J., & ZURAWSKI, VR. (1986). IODINATION OF MONOCLONAL-ANTIBODIES FOR DIAGNOSIS AND RADIOTHERAPY USING A CONVENIENT ONE VIAL METHOD. Journal of Nuclear Medicine, 27(12), 1890-1895.

1985

TOOZE, J., TOOZE, S., HAISMA, H., & HILGERS, J. (1985). ATT20 PITUITARY-TUMOR CELLS CONTAIN MOUSE MAMMARY-TUMOR VIRUS AND INTRACISTERNAL A-TYPE PARTICLES IN ADDITION TO MURINE LEUKEMIA-VIRUS. European Journal of Cell Biology, 39(1), 224-231.
HAISMA, H. (1985). INVIVO DETECTION OF TUMORS AND METASTASES WITH (MONOCLONAL) ANTIBODIES. The Netherlands Journal of Medicine, 28(3), 108-111.
HAISMA, H., HILGERS, J., DENOTTER, W., & ZURAWSKI, VR. (1985). IODINATION OF MONOCLONAL-ANTIBODIES FOR DIAGNOSIS AND RADIOTHERAPY USING A CONVENIENT ONE VIAL METHOD. British Jounal of Cancer, 52(4), 645-645.
GOEDEMANS, WT., DEJONG, MMT., HAISMA, H., & HILKENS, J. (1985). STABILITY OF IN-111 LABELED MONOCLONAL-ANTIBODY AGAINST HUMAN-MILK FAT GLOBULE ANTIGEN - IMAGING OF HUMAN-BREAST CANCER XENOGRAFTS IN NUDE-MICE. Pharmaceutisch weekblad-Scientific edition, 7(1), 27-27.
HAISMA, H., & HILGERS, J. (1985). USE OF MONOCLONAL-ANTIBODIES FOR DETECTION AND THERAPY OF CARCINOMAS. European journal of obstetrics gynecology and reproductive biology, 19(6), 358-361.

1984

HAISMA, H., GOEDEMANS, W., & HILKENS, J. (1984). IMPROVED TUMOR-LOCALIZATION USING SUBTRACTION OF INDIUM-LABELED SPECIFIC AND GALLIUM-LABELED NON-SPECIFIC ANTIBODY. British Jounal of Cancer, 50(4), 555-555.
Haisma, H., GOEDEMANS, W., DEJONG, M., HILKENS, J., HILGERS, J., DULLENS, H., & DENOTTER, W. (1984). Specific localization of In-111-labeled monoclonal antibody versus 67-Ga-labeled immunoglobulin in mice bearing human breast carcinoma xenografts. Cancer Immunology Immunotherapy, 17(1), 62-65. https://doi.org/10.1007/BF00205499
Last modified:15 June 2020 12.52 p.m.
printView this page in: Nederlands
Follow the UGfacebook twitter linkedin rss instagram youtube